Named Bioactive Compounds · Compound
Solamargine
Moderate Evidencealkaloid
Hermetica Superfood Encyclopedia
Solamargine is a steroidal alkaloid glycoside found in Solanum species that demonstrates anti-cancer activity through apoptosis induction and cell cycle arrest. The compound works by activating multiple death receptor pathways and inhibiting P-glycoprotein-mediated drug resistance.
Solamargine is a steroidal glycoalkaloid naturally found in plants of the Solanaceae family, including Solanum aculeastrum fruits, Solanum nigrum, eggplant (Solanum melongena), and fungal endophytes like Aspergillus flavus. It is extracted through ultrasonic maceration in methanol, followed by chromatographic purification techniques, with identity confirmed by NMR and mass spectrometry (m/z 868.5077 [M+H]+).
No human clinical trials, randomized controlled trials, or meta-analyses have been conducted with solamargine. All available research is limited to in vitro studies examining cytotoxicity in cancer cell lines and P-glycoprotein inhibition via rhodamine-123 assays.
No clinically studied dosage ranges are available as no human trials have been conducted. In vitro studies used crude extracts and isolated solamargine dissolved in DMSO, but doses have not been established for human use. Consult a healthcare provider before starting any new supplement.
Solamargine is not a nutrient or food but a steroidal glycoalkaloid (C45H73NO15, MW ~868 g/mol) found primarily in Solanaceae family plants. It is a triose glycoside of the aglycone solasodine, consisting of solasodine linked to a trisaccharide chain of L-rhamnose–D-glucose–L-rhamnose (chacotriose). Key biochemical characteristics: • Aglycone core: Solasodine (a nitrogen-containing steroidal sapogenin, C27H43NO2) • Sugar moiety: Chacotriose (α-L-rhamnopyranosyl-(1→2)-[α-L-rhamnopyranosyl-(1→4)]-β-D-glucopyranose) • Typical concentrations in source plants: Found at approximately 0.1–2.0% dry weight in fruits and leaves of Solanum species (e.g., Solanum nigrum, Solanum incanum, Solanum aculeastrum); concentrations vary significantly by species, plant part, and maturity stage • Solubility: Poorly water-soluble; moderately soluble in organic solvents (methanol, ethanol, DMSO) • Bioavailability: Oral bioavailability is considered low due to poor aqueous solubility, potential degradation in the gastrointestinal tract, and first-pass hepatic metabolism; the glycoside bond may be partially hydrolyzed by gut microbiota releasing solasodine; no definitive human pharmacokinetic data are available • No macronutrient value (zero calories, protein, fat, or carbohydrate contribution at pharmacologically relevant doses) • No vitamin or mineral content • Bioactive classification: Cytotoxic glycoalkaloid with demonstrated in vitro activity against multiple cancer cell lines (IC50 values typically ranging from 2–20 µM depending on cell line); mechanism involves TNF receptor upregulation, mitochondrial apoptotic pathway activation, and P-glycoprotein inhibition • Safety note: As a glycoalkaloid, solamargine exhibits general cytotoxicity and hemolytic activity; it is not approved as a dietary supplement or therapeutic agent; toxicity threshold in mammals is not well-characterized in clinical settings
Solamargine induces apoptosis through both intrinsic and extrinsic pathways, activating death receptors DR4 and DR5 while triggering mitochondrial cytochrome c release. The compound also inhibits P-glycoprotein efflux pumps, potentially reversing multidrug resistance in cancer cells. Additionally, solamargine arrests cell cycle progression at G0/G1 phase through p53-dependent mechanisms.
Current evidence for solamargine comes exclusively from in vitro cell line studies and animal models, with no human clinical trials published. Cell studies show anti-proliferative effects against cholangiocarcinoma, hepatocellular carcinoma, and lung cancer cell lines at concentrations of 10-50 μM. Animal studies in mice demonstrate tumor growth inhibition of 40-60% at doses of 5-15 mg/kg. The lack of human data significantly limits clinical applicability and safety assessment.
Safety data for solamargine in humans is extremely limited due to lack of clinical trials. As a steroidal alkaloid, potential concerns include hepatotoxicity and hemolytic effects observed in some Solanum compounds. The P-glycoprotein inhibition may significantly alter the pharmacokinetics of various medications including digoxin, cyclosporine, and chemotherapy drugs. Pregnancy and breastfeeding safety is unknown, and use should be avoided in these populations.
